PLoS ONE · 2014 · 132 citations · 36 references
MedicineOncologyPharmacologyCell SignalingChemotherapySignal TransductionCancer Therapy-related CardiotoxicityCardiotoxicity ManagementCardiovascular Molecular PhysiologyMetabolic ReprogrammingMetabolic Reprogramming In CancerPharmacodynamics Of Anticancer AgentsAmp-activated Protein Kinase InteractionCardiac Fatty Acid OxidationCardiotoxicityCardiotoxicity MitigationChemotherapy-induced CardiomyopathyDoxorubicin CardiotoxicityMechanisms Of Cardiac InjuryMetabolic Modulation
Doxorubicin (Dox) is one of the most widely used antitumor drugs, but its cumulative cardiotoxicity have been major concerns in cancer therapeutic practice for decades. Recent studies established that metformin (Met), an oral anti-diabetic drug, provides protective effects in Dox-induced cardiotoxicity. Met has been shown to increase fatty acid oxidation, an effect mediated by AMP activated protein kinase (AMPK). Here we delineate the intracellular signaling factors involved in Met mediated protection against Dox-induced cardiotoxicity in the H9c2 cardiomyoblast cell line. Treatment with low dose Met (0.1 mM) increased cell viabilities and Ki-67 expressions while decreasing LDH leakages, ROS generations and [Ca2+]i. The protective effect was reversed by a co-treatment with compound-C, an AMPK specific inhibitor, or by an over expression of a dominant-negative AMPKα cDNA. Inhibition of PKA with H89 or a suppression of Src kinase by a small hairpin siRNA also abrogated the protective effect of the low dose Met. Whereas, with a higher dose of Met (1.0 mM), the protective effects were abolished regardless of the enhanced AMPK, PKA/CREB1 and Src kinase activity. In high dose Met treated cells, expression of platelet-derived growth factor receptor (PDGFR) was significantly suppressed. Furthermore, the protective effect of low dose Met was totally reversed by co-treatment with AG1296, a PDGFR specific antagonist. These data provide in vitro evidence supporting a signaling cascade by which low dose Met exerts protective effects against Dox via sequential involvement of AMPK, PKA/CREB1, Src and PDGFR. Whereas high dose Met reverses the effect by suppressing PDGFR expression.
36
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation · 2001 · 5.4K citations
Douglas R. Bolster, Stephen J. Crozier, Scot R. Kimball et al. · Journal of Biological Chemistry · 2002 · 845 citations · Full text
Src Tyrosine Kinase Is a Novel Direct Effector of G Proteins
Yongchao Ma, Jianyun Huang, Shariq Ali et al. · Cell · 2000 · 419 citations · Full text